Sensitive

G6PD deficiency (G6PD A+ / A- component)

G6PD · rs1050829

Where this position leads

Drugs: Dapsone, nitrofurantoin and other oxidising drugs, Primaquine and tafenoquine, Rasburicase

What ClinVar records

Classification Conflicting classifications of pathogenicity for G6PD A+, Anemia, nonspherocytic hemolytic, due to G6PD deficiency, Inborn genetic diseases, Malaria, susceptibility to, G6PD deficiency and 1 more; criteria provided, conflicting classifications (1 of 4 stars, 33 submitters), last evaluated 2026-08-06. ClinVar record 100055 NM_000402.4(G6PD):c.466A>G (p.Asn156Asp)

Classification Conflicting classifications of pathogenicity for Anemia, nonspherocytic hemolytic, due to G6PD deficiency, Ovarian serous cystadenocarcinoma, Thyroid cancer, nonmedullary, 1; criteria provided, conflicting classifications (1 of 4 stars, 4 submitters), last evaluated 2026-01-19. ClinVar record 1546331 NM_001360016.2(G6PD):c.376A>T (p.Asn126Tyr)

What this is ClinVar's aggregate record for this position (as of its 2026-10-19 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.

What each result means

C/C Two copies of the variant allele, or one copy in a male. What this means depends on whether rs1050828 is also present: together they make the A- allele, which is deficient. Alone this is the A+ allele, which is not.

T/C One copy of the variant allele. This position defines the A+ allele on its own, which has near-normal activity; it becomes the deficient A- allele only when it travels together with rs1050828. Read one without the other and the answer is incomplete.

T/T The reference base at this position.

This position is only interpretable alongside rs1050828. Neither is a substitute for measuring enzyme activity.

Source

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Gammal RS, Pirmohamed M, Somogyi AA, Morris SA, Formea CM, Elchynski AL, Oshikoya KA, McLeod HL, Haidar CE, Whirl-Carrillo M, Klein TE, Caudle KE

and 1 more — show all

Relling MV

Clinical pharmacology and therapeutics · 2023 · PMID 36049896

Questions about rs1050829

What is rs1050829?

rs1050829 is a single position in the genome, in or near the G6PD gene. Published research associates it with g6pd deficiency (g6pd a+ / a- component). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs1050829 linked to?

On MyGeneLog this position is linked to G6PD Deficiency. The research behind each link, and its sources, are set out on that condition page.

Does rs1050829 affect how medicines work?

G6PD carries pharmacogenomic findings for Dapsone, nitrofurantoin and other oxidising drugs, Primaquine and tafenoquine, Rasburicase. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.

Does having rs1050829 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs1050829 come from?

CPIC Guideline for G6PD Genotype and Medication Use (Clin Pharmacol Ther 2023, PMID 36049896). Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

G6PD deficiency (G6PD A+ / A- component) (rs1050829). MyGeneLog™. https://www.mygenelog.com/variants/rs1050829

← See all variants